摘要
目的观察雷米普利与厄贝沙坦联合治疗心力衰竭(HF)合并稳定型心绞痛(AP)的疗效与安全性。方法90例HF合并AP的患者在常规治疗的基础上,随机分为:A组口服雷米普利、B组口服厄贝沙坦和C组两药联合治疗,观察8周。治疗前、后分别进行NYHA分级,行血生化、肝肾功能、12导联心电图及超声心动图检查。结果C组治疗后心绞痛发作次数、硝酸甘油消耗量、NST和ΣST、血清脑钠肽(BNP)水平、超声心动图指标均有改善(P<0.05),且比A、B组改善更为显著;三组不良反应发生率相仿(P>0.05)。结论雷米普利与厄贝沙坦联合治疗HF合并AP不仅优于单用两药,而且是一种安全的治疗方法。
Objective To compare the therapeutic effect and safety of Ramipril, Irbesaltan and Ramipril combined with Irbesartan for treatment of heart failure and angina pectoris. Methods 90 patients with heart failure and stable angina pectoris treated with conventional therapy were randomly assigned to group A （treated only with Ramipril） ,group B（treated only with Irbesartan） and group C（treated with both Ramipril and Irbesartan） for 8 weeks to observe the therapeutic effect and safety. The changes of NYHA class,blood electrolytes, liver and renal function, 12-lead electrocardiogram and echocardiography were examined before and after treatment. Results The angina pectoris attacks 、 Nitroglycerin dosage,ST segment move down,brain natriurefie pepfide （BNP）,the indexes of echocardiography were improved more significantly after treatment in group C than the two other groups （ P 〈 0.05）, the frequency of adverse reaction of three groups was similar（ P 〉 0.05）. Condusions Not only does the therapeutic effect of Ramipril combined with Irbesartan for treatment for heart failure and angina pectoris surpass that of Ramipril or Irbesartan alone, but also it is a safe medicine.
出处
《心脑血管病防治》
2008年第5期287-289,296,共4页
CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
